From GlobeNewswire: 2025-02-14 18:31:15

Dr. Ryan Saadi, Founder and CEO of Tevogen Bio, reaffirms commitment to preserving equity for shareholders. Emphasizes efficiency, asset ownership, and revenue path in biotech financing discussions. Tevogen Bio believes assets are valued in billions, with high market cap per employee. Self-sustaining financing strategy without selling equity. Company challenges traditional biotech financing norms for long-term sustainability, committed to accessible immunotherapies. Positive safety data reported in clinical trials, key intellectual property assets wholly owned by Tevogen. Leadership focused on accessible personalized therapeutics and disruptive business models. Forward-looking statements caution on risks and factors affecting performance.

For more information:
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]



Read more at GlobeNewswire: Tevogen Bio CEO Reinforces Commitment to Retention of